Amgen Reminds Us of Its Biotech Bloodlines; Analyst Day Notes (AMGN)
Amgen (AMGN) is one of the founding fathers of biopharma, but after showing its age in recent years with slowing drug sales and swirling safety concerns, share valuations have fallen dramatically from the high-20’s level Amgen once commanded.
We haven’t treated this company like a biotech in a long time, but Amgen is actually trading up [...]
More on this topic
(What's this?)
These Biotech Stocks Are Just What the Doctor Ordered
(Investment U, 1/28/10)
Small-Cap Biotech Stocks: Why This Sector Is Set for a Huge Year
(Investment U, 1/6/10)
“Make 66% On This Biotech Stock By May 1″ Steve Christ
(Stock Gumshoe, 12/18/09)
-
-
-
Investopedia Commentary- 3 Retail Rocket Stocks (M, ROST, SPY, FDO, XRT)
- Pharmaceutical Profits That Aren't For The Dogs (MRK, SNY, PFE, PETS, CENT, NVS, ABT))
- Terex Reshapes For The Future (TEX, BUCY, CAT, DE)
- Is Best Buy Still The Better Buy In Electronics? (BBY, RSH, SHLD, WMT, AMZN)
- Oil Service Costs To Move Higher (CLR, XCO, SD, BEXP)
About
Pragmatic commentary on U.S. & global investing, demographics & secular trends, and the valuation of anything worth valuing. Objective, unbiased research; We believe in minimal design, zero gimmicks, and maximum results.
Subscribe to feed
Search
Secular Trends Holdings
- Secular Trends Portfolio Real-Time Positions
- The Fuel That Fed the Subprime Meltdown (Written in September 2007)
- Performance Studies on the DJIA & Fundamental Value Stocks (11/22/08)
- Las Vegas Sands - Are They Sustainable in 2009? (Published 11/15/08)
Older Posts That Folks Seem to Like
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 Generic License.